Vaccine dream team

An experienced vaccine development team, vector technology that has been tested in humans and two neoantigen programs poised to enter the clinic helped Nouscom AG land a €42 million ($48.8 million) series B round.

Abingworth led the tranched round, which closed on Nov. 6, and was joined by fellow new investor 5AM Ventures and existing investors LSP and Versant Ventures. Details of the tranches are undisclosed...